Bat tests positive for rabies in Chatham-Kent, prompting warning from health unit
They are also urging people to take other measures to protect themselves, their families and their pets.
"Rabies remains nearly 100 per cent fatal once clinical symptoms develop, and without immediate medical intervention following an exposure, the outcome is almost always tragic," said Dr. Shanker Nesathurai, acting medical officer of health for Chatham-Kent, in a news release.
"That's why prompt reporting of any bite or scratch and timely post-exposure treatment is extremely important."
Rabies is a viral disease that infects the central nervous system of mammals, including humans. It is transmitted through the saliva of infected animals, most often via bites or scratches.
It's common for bats to be infected with rabies, so the positive test in Chatham-Kent is "concerning but not unexpected," CK Public Health said in the release.
Other animals that can spread rabies include raccoons, skunks, foxes, coyotes, dogs and cats.
Human rabies cases in Canada are rare, but any exposure to a rabid animal carries a serious risk, the health unit said.
It urged people to take the following steps to protect themselves and their loved ones and pets.
Ensure pets are vaccinated against rabies and keep their records up to date.
If you suspect your pet has been exposed to a rabid animal, contact your veterinarian immediately.
Supervise pets outdoors—keep them on a leash or within a securely fenced area.
Stay away from wild, stray or aggressive animals. Do not touch, feed or move young, sick or injured wildlife.
Never keep wild animals as pets; they can harbour diseases harmful to humans and domestic animals.
Report stray animals to local animal control services.
If you find bats or other wild animals inside your home, contact a licensed pest control company to safely remove them and seal any entry points.
Officials advise anyone that has had contact with a bat or has been bitten or scratched by an animal to seek medical attention immediately report the exposure promptly to CK Public Health.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Myasthenia Gravis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myasthenia Gravis pipeline constitutes 20+ key companies continuously working towards developing 22+ Myasthenia Gravis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Myasthenia Gravis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. ' Myasthenia Gravis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myasthenia Gravis Market. Some of the key takeaways from the Myasthenia Gravis Pipeline Report: Companies across the globe are diligently working toward developing novel Myasthenia Gravis treatment therapies with a considerable amount of success over the years. Myasthenia Gravis companies working in the treatment market are Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others, are developing therapies for the Myasthenia Gravis treatment Emerging Myasthenia Gravis therapies in the different phases of clinical trials are- Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others are expected to have a significant impact on the Myasthenia Gravis market in the coming years. In May 2025, The FDA approved a new therapy for generalized myasthenia gravis (gMG), a condition characterized by severe muscle weakness, rapid fatigue, and challenges with speech and swallowing. This new treatment, called nipocalimab and marketed as Imaavy, provides a long-lasting option for symptom management, benefiting approximately 100,000 people affected by gMG in the U.S. It is the first and only therapy designed to address the underlying cause of the disease in adults and adolescents aged 12 and older who possess specific antibodies associated with gMG. In April 2025, Nipocalimab-aahu is a human IgG1 monoclonal antibody designed to target the neonatal Fc receptor (FcRn) with high affinity, thereby reducing circulating IgG levels. Its approval was supported by results from the Phase 3 Vivacity-MG3 trial ( ID: NCT04951622), a randomized, double-blind, placebo-controlled study. The trial involved adult patients with generalized myasthenia gravis (gMG), classified as class II to IV by the Myasthenia Gravis Foundation of America, who had an inadequate response to standard therapies, indicated by an MG-ADL score of 6 or above. In April 2025, Promising results from the Phase 3 clinical trial (NCT05737160) assessing the safety and efficacy of Telitacicept (RC18; brand name: 泰爱®) in patients with generalized myasthenia gravis (gMG) were shared during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting. In April 2025, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotech company focused on developing cell therapies for autoimmune disorders, has reported 12-month efficacy and safety results from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). Patients who received a single six-week treatment course of Descartes-08 showed sustained improvement in MG symptoms, which persisted through the 12-month follow-up evaluation. In March 2025, Immunovant decided not to pursue regulatory approval for its myasthenia gravis (MG) treatment, batoclimab, despite the Phase III study meeting its primary endpoint of reducing disease symptoms. Instead, the company will leverage the data to further develop its alternative therapy, IMVT-1402. The Phase III randomized trial (NCT05403541) assessed the impact of weekly or bi-monthly doses of batoclimab on acetylcholine receptor antibody-positive (AChR+) patients, using the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over a 12-week period. In December 2024, Cartesian Therapeutics revealed updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate, Descartes-08, for generalized myasthenia gravis (MG). The results showed sustained responses at the 12-month mark. The double-blind, placebo-controlled, crossover trial (NCT06038474) was open-label and involved 36 heavily pre-treated, symptomatic patients. Half of the participants received a placebo, while the other half were treated with Descartes-08, both administered as six weekly outpatient infusions without prior chemotherapy preconditioning. Myasthenia Gravis Overview Myasthenia Gravis is a chronic autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of voluntary muscles. The name, which translates to "grave muscle weakness," reflects the primary symptom of the condition. Myasthenia Gravis occurs when the immune system produces antibodies that interfere with the communication between nerves and muscles. Get a Free Sample PDF Report to know more about Myasthenia Gravis Pipeline Therapeutic Assessment- Emerging Myasthenia Gravis Drugs Under Different Phases of Clinical Development Include: Povetacicept: Alpine Immune Science TOL 2: Toleranzia MuSK-CAART: Cabaletta Bio RLYB116: Rallybio ALXN2050: Alexion Pharmaceuticals TAK-079: Takeda Descartes-08: Cartesian Therapeutics Telitacicept: RemeGen I nebilizumab: Horizon Therapeutics Myasthenia Gravis Route of Administration Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Infusion Intradermal Intramuscular Intranasal Oral Parenteral Subcutaneous Topical Molecule Type Myasthenia Gravis Molecule Type Myasthenia Gravis Products have been categorized under various Molecule types, such as Vaccines Monoclonal Antibody Peptides Polymer Small molecule Product Type Myasthenia Gravis Pipeline Therapeutics Assessment Myasthenia Gravis Assessment by Product Type Myasthenia Gravis By Stage and Product Type Myasthenia Gravis Assessment by Route of Administration Myasthenia Gravis By Stage and Route of Administration Myasthenia Gravis Assessment by Molecule Type Myasthenia Gravis by Stage and Molecule Type DelveInsight's Myasthenia Gravis Report covers around 22+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Myasthenia Gravis product details are provided in the report. Download the Myasthenia Gravis pipeline report to learn more about the emerging Myasthenia Gravis therapies Some of the key companies in the Myasthenia Gravis Therapeutics Market include: Key companies developing therapies for Myasthenia Gravis are - CuraVac, Grifols SA, Immunovant, Mitsubishi Tanabe Pharma, Novartis, Alexion Pharmaceutical, Argenx, Astellas Pharma, UCB Pharma, Bausch Health, and others. Myasthenia Gravis Pipeline Analysis: The Myasthenia Gravis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myasthenia Gravis Treatment. Myasthenia Gravis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Myasthenia Gravis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myasthenia Gravis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Myasthenia Gravis drugs and therapies Myasthenia Gravis Pipeline Market Drivers Increasing prevalence of Myasthenis gravis, growing awareness regarding the myasthenia gravis diagnosis options, surge in geriatric population with autoimmune disease are some of the important factors that are fueling the Myasthenia Gravis Market. Myasthenia Gravis Pipeline Market Barriers However, limited reimbursement policies, high cost associated with the treatment and other factors are creating obstacles in the Myasthenia Gravis Market growth. Scope of Myasthenia Gravis Pipeline Drug Insight Coverage: Global Key Myasthenia Gravis Companies: Alpine Immune Science, Toleranzia, Cabaletta Bio, Rallybio, Alexion Pharmaceuticals, Takeda, Cartesian Therapeutics, RemeGen, Horizon Therapeutics, and others Key Myasthenia Gravis Therapies: Povetacicept, TOL 2, MuSK-CAART, RLYB116, ALXN2050, TAK-079, Descartes-08, Telitacicept, Inebilizumab, and others Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers Table of Contents 1. Myasthenia Gravis Report Introduction 2. Myasthenia Gravis Executive Summary 3. Myasthenia Gravis Overview 4. Myasthenia Gravis- Analytical Perspective In-depth Commercial Assessment 5. Myasthenia Gravis Pipeline Therapeutics 6. Myasthenia Gravis Late Stage Products (Phase II/III) 7. Myasthenia Gravis Mid Stage Products (Phase II) 8. Myasthenia Gravis Early Stage Products (Phase I) 9. Myasthenia Gravis Preclinical Stage Products 10. Myasthenia Gravis Therapeutics Assessment 11. Myasthenia Gravis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Myasthenia Gravis Key Companies 14. Myasthenia Gravis Key Products 15. Myasthenia Gravis Unmet Needs 16 . Myasthenia Gravis Market Drivers and Barriers 17. Myasthenia Gravis Future Perspectives and Conclusion 18. Myasthenia Gravis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
26 minutes ago
- Globe and Mail
CYSM Shapers Are Offering Plus-Size Shapewear in Bid to Change the Fashion Conversation
CYSM Shapers is a body shaper manufacturer with over three decades of experience and 1,000,000+ products sold. CYSM Shapers has showcased its latest lineup of plus-size shapewear, featuring products sized up to 3XL to help plus-size women who seek supportive shapewear get the results they want without feeling restrictive or any detriment to their health. A company representative stated: "Here at CYSM, we celebrate body diversity, with sizes ranging from S to 3XL. The CYSM plus-size collection is designed for comfort and confidence. It's perfect for plus-size women looking for supportive shapewear that doesn't feel restrictive." CYSM's Premium Shapewear lineup is celebrated by top plastic surgeons worldwide for its use of top-tier quality materials that are mixed with advanced technology to strike that perfect balance of comfort, compression, and skincare, perfectly suited for daily wear and plus-size users. The fabric used in the process is highly breathable and guarantees a fresh feel regardless of size. For extra optimization, the company added a set of adjsutable strals and zero internal seams. "Feel confident and comfortable every day," the team stated, adding that "insecurities about your body can impact self-esteem. Our Premium Shapewear offers support and comfort to enhance your curves, empowering you to feel beautiful and confident every day." And while CYSM promotes this lineup as body confidence shapewear, the CYSM Inclusive Shapewear 2025 collection offers so much more. As the company representative pointed out, CYSM started its journey over 30 years ago by specializing in post-op recovery shapewear. That is why, to this day, CYSM Shapers, and especially the Premium Shapewear lineup, guarantee maximum comfort, support, and constant freshness to allow for full-day wear with no struggle. CYSM's exclusive BIO Therapy Technology plays a key role in making the company's shapewear extra suitable for plus-size women. It offers a mix of compression and skincare because it incorporates microcapsules that release active ingredients into the skin. The active ingredients deliver a marine algae infusion that helps restore skin elasticity and nurture it with minerals, all while providing antibacterial protection and making the shapewear fresher. The company representative also pointed out that all CYSM Shapers undergo rigorous testing to pass the OEKO-Tex Standard 100, a globally recognized certification and testing system for textiles. A satisfied customer named Mandy wrote in her five-star review of one of CYSM's best-selling shapers, "I love this compression garment! I'm using it after having a tummy tuck, and I can't go without it! It's like I'm dependent on this garment! I hate taking it off to clean it." More information about CYSM Shapers, the company's history, technology, and the full product lineup, can all be found on the official website. Media Contact Company Name: CYSM Shapers Contact Person: CYSM Team Email: Send Email Phone: +13235861600 Address: 5807 Pacific Blvd, Huntington Park, CA 90255 Country: United States Website:
CTV News
26 minutes ago
- CTV News
Sault family gifts $200K to Group Health Centre
A recent photo of the Ruscio family. Anna and Tony Ruscio (front row) and their four children, Barbara, Domenic, Linda and Marcella (back row). (Supplied/Group Health Centre) Group Health Centre has received a $200,000 donation from Tony and Anna Ruscio and their family to purchase new medical equipment for its surgical and ear, nose and throat departments. The contribution, announced this Tuesday, is earmarked for state-of-the-art equipment, including vital signs monitors, a gastroscope, a surgical table and a modernized monitor and light system for ear, nose and throat procedures. A lasting impact on local healthcare In a news release, Lil Silvano, the medical group's president and CEO, expressed gratitude for the gift, highlighting its significance for patient care in the region. 'This donation will have both an immediate and lasting impact, helping us provide our surgical and (ear, nose and throat) teams with the tools they need to serve patients efficiently and effectively,' Silvano said. The new equipment will be used to support care for patients throughout the Algoma District. 'Our gift to the Group Health Centre is a way of giving back – helping ensure that every neighbour, friend, and family member can access the best possible care, close to home.' — The Ruscio Family Giving back to a community that shaped their lives The Ruscio family, long recognized as pillars of the Sault Ste. Marie community, stated the donation was a way to give back to the place they call home. 'Sault Ste. Marie will always be home to us. It's where we learned the value of community, and where we've been shaped by the care, kindness and support of so many,' the Ruscio family said in the news release.
